Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04164966

Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes

The purpose of this study is to measure the levels of certain substances (biomarkers) in the body that may indicate the triggers of Type 1 Diabetes, to find a better way to diagnose the disease, as well as to follow its progression.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

12 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

AdventHealth Translational Research Institute

Orlando, Florida, 32804, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Type 1 Diabetes (T1D)

  • Age 12-18 years inclusive
  • Diagnosis of T1D according to American Diabetes Association (ADA) criteria with an acute onset and presence of islet associated autoantibody by history.
  • T1D duration of ≤ 3 months from the diagnosis

Healthy Normal Volunteers (HNV)

  • Age 12-18 years inclusive
  • No personal history of diabetes according to ADA criteria
  • No history of T1D or insulin treated diabetes in first degree relatives (FDR)

Exclusion criteria

Acute or chronic medical conditions or medication that would contraindicate the participation in the research testing or could potentially affect metabolic and immune function including, but not limited to:

  • History of type 2 diabetes
  • Suspicion of non-type 1 diabetes (e.g. maturity onset diabetes of the young or secondary diabetes)
  • History of thyroid dysfunction in which the participant has not been on a stable dose (at least 6 weeks prior to enrollment) of thyroid replacement medication or antithyroid drugs.
  • History of cancer within the last 5 years (skin cancers, with the exception of melanoma, may be acceptable).
  • History of organ transplant
  • History of HIV, active Hepatitis B or C, or Tuberculosis
  • Pregnancy, lactation or 6 months postpartum from the scheduled date of collection
  • Psychiatric disease prohibiting adherence to study protocol
  • Use of oral or injectable anti-hyperglycemic agents: metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, acarbose, GLP-1 analogs.
  • Use of any other medications known to influence glucose, fat and/or energy metabolism within the last 3 months (e.g., growth hormone therapy, glucocorticoids [steroids], prescribed medications for weight loss, etc.)
  • Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete study visits

Treatment and study plan

Primary outcomes

  1. Characterization of circulating β cell-specific exosomes in children with T1D and healthy normal controls using baseline samples

    Time frame: 2-3 hours

    Measure will be the number (concentration) of circulating beta-cell specific exosomes. If the characterization of circulating beta-cell specific exosomes is not feasible in children with T1D due to the potentially limited low input amount of this type of exosomes in the circulation of these participants, an alternative analysis will be implemented.

Sponsors and collaborators

Lead sponsor

AdventHealth Translational Research Institute

Other

Registry information

Acronym: HONEY

Important dates

Study start
2019
Primary completion
2024
Study completion
2026
First posted
Nov 15, 2019
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.